Ownership and insider activity for Pyxis Oncology, Inc. (PYXS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors.
Price
| Price | $3.34 |
| Market Cap | $212M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-04 | Civik Thomas | A-Award | 2,503,050 | $9.7M |
| 2026-08-20 | Dupont Jakob | A-Award | 46,000 | $144K |
| 2026-08-12 | Civik Thomas | A-Award | 250,956 | $374K |
| 2026-06-30 | GordonMD Global Investments LP | |||
| 2026-06-30 | GordonMD Global Investments LP | 4,900,039 | $16.1M | |
| 2026-06-30 | Dupont Jakob | M-Exempt | 35,000 | $56K |
| 2026-06-30 | Dupont Jakob | M-Exempt | 35,000 | $56K |
| 2026-06-30 | Dupont Jakob | S-Sale | 35,000 | $107K |
| 2026-03-24 | Dupont Jakob | A-Award | 45,867 | $62K |
| 2026-03-24 | Wadhane Jitendra | A-Award | 109,461 |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.7M | $8.1M | $274.7M | $179.3M | $9.7M | $19.5M | $15.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | $109.6M | $107.5M | $51.4M |
| Receivables | 0 | 0 | 0 | $598000 | $21000 | 0 | $700000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $19.7M | $8.1M | $278.7M | $186.6M | $124.6M | $132.4M | $72.1M |
| Property, Plant & Equipment | $76000 | $1.9M | $1.2M | $24.8M | $24.8M | $22.1M | $19.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | $24.3M | $2.6M | 0 |
| Total Assets | $19.8M | $10.2M | $280.0M | $211.4M | $173.7M | $157.2M | $91.5M |
| Accounts Payable | $491000 | $1.1M | $12.0M | $7.1M | $3.9M | $4.9M | $10.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $733000 | $3.7M | $18.7M | $31.6M | $25.8M | $17.7M | $21.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $22.7M | $25.8M | $18.7M | $50.6M | $48.0M | $36.4M | $38.1M |
| Retained Earnings | -$2.9M | -$15.7M | -$91.7M | -$212.4M | -$286.2M | -$363.6M | -$443.2M |
| Total Equity | -$2.9M | -$15.6M | $261.3M | $160.8M | $125.7M | $120.8M | $53.4M |
| Total Debt | $15000 | $780000 | $165000 | $18.9M | $21.3M | $20.2M | $18.7M |
| Net Debt | -$19.7M | -$7.3M | -$274.6M | -$160.4M | -$98.0M | -$106.7M | -$48.2M |
| Working Capital | $19.0M | $4.4M | $260.0M | $155.0M | $98.8M | $114.8M | $51.0M |
Financial Health
| Debt / Equity | 1.56 |
| Current Ratio | 1.34 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -7.88 |
Profitability
| Return on Equity | -215.23% |
| Return on Invested Capital | -314.66% |
| Return on Assets | -161.55% |
| Gross Margin | 99.76% |
| Operating Margin | -834.44% |
| Net Margin | -803.83% |
Related companies: AVIR · CRBU · ENTA · FHTX · HUMA · IMRX · TNYA
Explore sector: Healthcare · Biotechnology
More sections of PYXS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks